imec

The semiconductor industry is undergoing a rapid transformation. Artificial intelligence (AI) applications, such as agentic and physical AI, push compute demands to unprecedented heights, prompting the semiconductor industry to push the boundaries of 2nm technology and beyond. Yet, as we move to these advanced semiconductor technology nodes, it has become increasingly challenging for academic research to remain closely connected with the fast-evolving industrial developments, limiting academic researchers in driving innovation. Europe’s NanoIC pilot line, a pioneering European initiative, hosted by imec, is addressing this challenge by offering pathfinding process design kits (P-PDKs). To cover the potential of these P-PDKs and their impact on Europe’s semiconductor ecosystem, we sat together with Professor Mehdi Tahoori (professor at Karlsruhe Institute of Technology) and Anita Farokhnejad (DTCO Program Manager at imec).SEMI: What exactly is a P-PDK, and how does it differ from traditional PDKs?Farokhnejad: At its core, a process design kit (PDK) is a software environment that enables circuit designers to simulate, validate, and optimize chip designs using realistic models of chip technology. Consider it a blueprint or a simulation toolkit allowing chip designers to explore performance, power, and manufacturability of a new chip architecture in a virtual sandbox. What sets P-PDKs apart is that they anticipate future technologies. Unlike traditional PDKs, which are based on existing technologies, P-PDKs are built on predictive models of future nodes and architectures. This allows researchers to explore system-level trade-offs, assess architectural implications, and prepare design flows before a technology reaches maturity. SEMI: Why are they so crucial for academia?Tahoori: For decades, academic researchers could contribute to semiconductor innovation using abstraction layers that allowed them to design and test new architectures without direct access to the latest technologies. This approach worked well until the industry reached the 20-nanometer node. At that point, the complexity of semiconductor design increased, with the introduction of advanced device architectures like FinFETs, nanosheets, Forksheets, CFETs, and novel integration solutions such as 3D stacking and chiplet integration.Transistor scaling in the AI eraTraditional abstraction models could no longer keep up with these advances, and the gap between academic research and industrial practice began to widen. This growing gap started to limit academia’s ability to participate in semiconductor paradigm shifts, such as CMOS 2.0 and new computing architectures. P-PDKs, enabled by the NanoIC pilot line, aim to bridge this gap, restoring the connection between academic thinking and industrial progress.SEMI: How does this support semiconductor innovation in Europe?Tahoori: Universities are ideally positioned to drive out-of-the-box innovation and invent new paradigms for computing. This is where universities truly excel. But to do that, they need access to the latest technologies and tools. We see for example a strong focus on the AI revolution and how the microelectronics industry is enabling that transformation. To meet the demands of AI applications and the computing power they require, we need to design new computing architectures based on advanced technology nodes. This is precisely the academic area of expertise. To design these new AI computing architectures, however, we need the most advanced technologies available. The P-PDKs for advanced nodes provided by the NanoIC pilot line now make this kind of research possible at universities. Something that was not feasible before.Additionally, the P-PDKs also provide an important reference technology and platform to benchmark and validate these innovations within a next-generation design roadmap. This means researchers can test their novel architectures against realistic process and performance metrics.SEMI: Are they only available for academia?Farokhnejad: The NanoIC P-PDKs are meant to be accessible to foster innovation across Europe’s semiconductor ecosystem. These advanced PDKs are therefore also available to European research organizations, startups, and industry partners. Access is facilitated through Europractice, where eligible users can apply by signing a Design Kit License Agreement (DKLA). Once approved, they gain access to the PDKs.SEMI: What other technology nodes are NanoIC’s PDKs addressing?Farokhnejad: The first P-PDK was released in June (first version of the N2) and supports frontside and backside routing with TSVM, standard cell libraries, and multiple VT flavors for early-stage design exploration. Upcoming releases include new versions of the N2 P-PDK, as well as A14 and A7 PDKs, eDRAM and SOT memory PDKs, and advanced interconnect solutions such as redistribution layers (RDL), hybrid bonding, and interposers.Those interested in learning more about the NanoIC ecosystem and the research enabled by the P-PDKs can meet representatives and partners of the NanoIC pilot line during SEMICON Europa, November 18-21 at booth C2417 in Messe Munchen. More information about the initiative is also available on the NanoIC website.BiosMehdi Tahoori, Professor Chair of Dependable Nano-Computing - Karlsruhe Institute of Technology Mehdi B. Tahoori is Professor and Chair of Dependable Nano-Computing at the Karlsruhe Institute of Technology (KIT), Germany, and guest professor at imec, focusing on CMOS 2.0 and future chip technologies. He previously worked at Xilinx (USA), Fujitsu Labs (USA), and served as a junior professor at Boston Northeastern University (USA) and as a visiting professor at the University of Tokyo (Japan). He earned his B.S. from Sharif University (Iran) and M.S./Ph.D. from Stanford (USA). Prof. Tahoori is Deputy Editor-in-Chief of IEEE Design and Test Magazine, is a former Editor-in-Chief of Elsevier Microelectronic Reliability and has chaired major IEEE symposia. His honors include multiple best paper nominations and conference awards, the US National Science Foundation Early Faculty Development (CAREER) Award (2008), an ERC Advanced Grant (2022), and an IEEE fellowship.Anita Farokhnejad, DTCO Program Manager - imec Anita Farokhnejad earned her PhD from Universitat Rovira i Virgili (Spain), specializing in FEOL and device modelling. She joined imec in 2021 as an R D Engineer, focusing on BEOL optimization and future roadmap development. Collaborating closely with integration and physical design teams, she develops models for PnR data analysis and BEOL optimization. Her recent work on the enhanced Ring Oscillator (eRO) model aids in the early assessment of new materials and BEOL boosters. In August 2023, she advanced to team lead for PDK Enablement, translating advanced semiconductor nodes into Pathfinding-PDKs. Farokhnejad is also dedicated to education, conducting courses that make sophisticated technological concepts accessible to both industry veterans and aspiring engineers. Currently, she serves as Program Manager of DTCO at imec, where her contributions continue to drive innovation in the semiconductor industry.AcknowledgementThis work was enabled by the NanoIC pilot line. The acquisition and operation are jointly funded by the Chips Joint Undertaking, through the European Union’s Digital Europe (101183266) and Horizon Europe programs (101183277), as well as by the participating states Belgium (Flanders), France, Germany, Finland, Ireland and Romania. For more information, visit https://www.nanoic-project.eu.DisclaimerFunded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or Chips Joint Undertaking. Neither the European Union nor the granting authority can be held responsible for them. SEMI ContactJames Lam, Business Development ManagerEmail: [email protected]

In the rapidly-evolving semiconductor industry, maintaining a competitive edge is crucial. To position Europe at the forefront of global semiconductor innovation, imec is leading the NanoIC pilot line initiative. Aligned with the European Chips Act, this initiative is a strategic move to bolster Europe's leadership in key markets like high performance computing, automotive, and healthcare.SEMI spoke with Srikanth Samavedam and Jo De Boeck from imec, Belgium, to learn more about the NanoIC pilot line and to better understand its goals, challenges, and prospects. From transitioning to gate-all-around (GAA) nanosheet devices, to developing advanced memory technologies and interconnects, this conversation highlights the cutting-edge advancements made possible through collaboration across the industry’s value chain.SEMI: How is the NanoIC pilot line working to revolutionize the semiconductor industry, and what are its main objectives?Samavedam: The NanoIC pilot line is a European initiative aimed at bridging the gap between R D and industrial innovation. The project is creating a beyond-2nm system-on-chip (SoC) pilot line, developing advanced logic, memory, and interconnect technologies. This effort supports the European Chips Act's vision for leadership and competitiveness in global semiconductor innovation, particularly in critical markets like high performance computing, communication, automotive, energy, and healthcare. However, advanced technologies come with more complexity, and addressing these complexity challenges requires more mature module baseline flows. By improving baseline flow repeatability and variability while reducing defectivity, we can accelerate the development of future technologies. The NanoIC pilot line is working to provide access to these advanced technologies and baselines to develop future compute systems. This will help ensure European competitiveness across the industry – from semiconductor materials, equipment and design to systems and applications.SEMI: Who are the core partners involved in this initiative?De Boeck: Key partners of the pilot line include CEA-Leti, Fraunhofer-Gesellschaft, VTT Technical Research Centre of Finland, Tyndall National Institute, and the Center for Surface Science and Nanotechnology of the University POLITEHNICA of Bucharest. This project is also supported by the Flemish government, other participating states, and the Chips Joint Undertaking of the EU Chips Act.These institutions and organizations bring a wealth of knowledge and resources, and imec compliments their efforts by providing access to its global partnerships with key industry leaders. The NanoIC pilot line is helping strengthen Europe’s global semiconductor industry leadership while aligning efforts with other regional Chips Acts. SEMI: Can you elaborate on the significance of transitioning from field-effect transistors (FinFETs) transistors to GAA nanosheet devices in CMOS technology?Samavedam: The transition from FinFETs to GAA nanosheet devices is a significant advancement in CMOS device technology. FinFETs have been the backbone of CMOS technology from the 22nm to the 3nm node. But starting at the 2nm node, nanosheet devices will need to be introduced. Nanosheet devices, including variants like Forksheet devices, are expected to drive scaling and performance through three generations – 2nm, A14, and A10. Complementary FET (CFET) architectures are also expected to be introduced around 2031 at the A7 node, which will represent another major inflection point in CMOS device design. This progression requires extensive research into new materials, process modules, equipment, and advanced patterning capabilities using high numerical aperture extreme ultraviolet (high NA EUV) lithography – all of which will be implemented on the NanoIC pilot line. FIGURE PROVIDED BY IMEC │ SCHEMATIC ILLUSTRATION OF A FUTURE COMPUTE SYSTEM. THE SYSTEM IS MADE OF LARGE MULTI-DIE ELECTRICAL-OPTICAL INTERPOSER PROVIDING ELECTRICAL AND OPTICAL INTERCONNECTS BETWEEN THE VARIOUS CHIPLETS (CPUS, GPUS, HBM). ALSO SHOWN ARE CONNECTIONS TO PACKAGE SUBSTRATE, AS WELL AS FIBER CONNECTORS AND AN INTEGRATED LASER SOURCE. CENTRAL PROCESSING UNIT (CPU); GRAPHICS PROCESSING UNIT (GPU); HIGH BANDWITH MEMORY (HBM); PROCESSING UNIT THAT CAN INCLUDE CPUS, GPUS, AND OTHER SPECIALIZED PROCESSORS (XPU); APPLICATION-SPECIFIC INTEGRATED CIRCUIT (ASIC); ELECTRONIC INTEGRATED CIRCUIT (EIC); FF-LEVEL: FEMTOFARAD-LEVEL; FIELD-PROGRAMMABLE GATE ARRAY (FGPA); GAAS QD: GALLIUM ARSENIDE QUANTUM DOT; INTEGRATED SILICON PHOTONICS PLATFORM 300MM (ISIPP300); REDISTRIBUTION LAYER (RDL); SILICON PHOTONICS (SIPHO); THROUGH PACKAGE VIA (TPV). SEMI: What are the key innovations necessary for advancing memory technology?Samavedam: As SRAM scaling slows, the exploration of novel, dense embedded memory concepts will become imperative. Technologies like spin orbit torque magnetic RAM (SOT-MRAM) and 2-transistor 0-capacitor (2T0C) embedded DRAM using deposited semiconductors like indium gallium zinc oxide (IGZO) are promising. These innovations address memory capacity and bandwidth challenges from new workloads in compute systems. Additionally, developing a 3D memory platform to explore future memory options will be essential for improving SRAM and DRAM. These advancements will help meet the demands of new applications like machine learning, augmented and virtual reality, and autonomous vehicles.SEMI: How do advanced interconnect technologies contribute to the future of semiconductor design?Samavedam: Advanced interconnect technologies, like chip-to-chip lateral (2.5D or interposer technologies) and vertical interconnects (3D technologies), play a crucial role in addressing memory capacity and bandwidth challenges. These technologies enable the partitioning of SoC functions into separate dies, allowing for more efficient and scalable designs. Advances like pitch scaling of micro-bumps and copper (Cu) hybrid bonding are facilitating this fine-grained partitioning of SoC functions. Additionally, optical interconnects and 3D interconnect-enabled co-packaging provide high-bandwidth and low-power connectivity at wafer scale. The rise of chiplet architectures and standardization will also increase the demand for low-cost, tight-pitch interconnect technologies like Cu/polymer redistribution layers.SEMI: How do your collaborators benefit from the NanoIC pilot line? De Boeck: One of the biggest collaborator benefits is the pilot line’s commitment to knowledge sharing through R D access and training. We invite foundries, IDMs, materials suppliers, equipment suppliers, and system companies/OEMs to jointly develop the materials, process modules, and integration flows to accelerate the development of beyond-2nm SoC technology pillars.Design pathfinding and system exploration process design kits (PDKs) will be available for start-ups, small- and medium enterprises, universities, and design and system companies to aid in prototyping and testing their designs. The NanoIC pilot line will also offer comprehensive training programs, including virtual PDK training, bootcamps for faculty, and internships and expert courses for students. To learn more, experts and key partners of the NanoIC pilot line will be presenting from 14 -16:40 at SEMICON Europa on November 12. imec’s program, ITF Chip into the Future, will highlight advancements in digital technology, capacity building through the European Chips Act, and the role of the NanoIC pilot line in accelerating beyond-2nm innovation. The conversation will also address industry requirements for pilot lines, emerging initiatives boosting Europe’s innovation and competitiveness, and perspectives on advanced materials and semiconductor equipment. Srikanth Samavedam, Senior Vice President of Semiconductor Technologies at imec, oversees programs in logic, memory, photonics, and 3D integration. Previously, he was a senior director at GlobalFoundries, leading 14nm FinFET technology into production and developing 7nm CMOS. Starting his career at Motorola, he worked on strained silicon and other advanced materials. He holds a Ph.D. in materials science and engineering from MIT and a master's degree from Purdue University. Jo De Boeck, Executive Vice President and Chief Strategy Officer at imec, oversees the company’s strategic direction and serves on its executive board. He joined imec in 1991 after earning his Ph.D. from KU Leuven and has since held various leadership roles, including head of imec’s Smart Systems and Energy Technology business unit and CTO. De Boeck is also a part-time professor at KU Leuven. Maria Daniela Perez / Communications Manager, SEMI EuropePhone: +49 160 2562977Email: [email protected]

SEMI spoke with imec Lars-Ake Ragnarsson, Program Director Sustainable Technologies and Systems (SSTS), about the semiconductor industry challenges to reduce environmental impact and how industry leaders can collaborate to get to the net zero.

Electronics industry experts and researchers will offer insights into ALD trends and adoption at Beneq ALD TechDay at SEMICON Europa 2023, Nov. 14-17 in Munich, Germany.

Coming in the wake of the COP27, the Smart and Green Manufacturing Summit at SEMICON Europa 2022 (Munich, 15-17 November) had a timely focus on the semiconductor industry’s contribution to meeting the United Nations’ target of limiting global warming to 1.5°C above pre-industrial levels.

Electronics industry experts will offer insights into key aspects of the radio frequency (RF) challenge – from materials and devices to ICs and modules – at ITF Beyond 5G at SEMICON Europa 2022, Nov. 15-18 in Munich, Germany.

Luc Van den hove, president and CEO at imec, spoke on semiconductor sustainability, healthcare trends and deep tech, and their implications for the semiconductor industry, sharing his views ahead of his keynote presentation at SEMI ISS Europe on May 30, 2022, in Brussels, Belgium.

The recent global pandemic redefined well-established paradigms in healthcare. The classic model involving frequent hospital visits is no longer viable due to the risk of contagion. The focus is now on remote and pervasive vital sign monitoring solutions and automated data processing for health assessment. Social-distancing-friendly technologies, such as wearables, implantables, insertables and ingestables that enable long-term monitoring, can help detect medical abnormalities both in individuals and large populations. SEMI spoke with Carlos Agell, program manager and principal member of Technical Staff at imec, about remote vital sign monitoring using innovative form factors and methodologies. imec’s healthcare technology vison for remote care systems will be the focus of Agell’s presentation at the SEMI MedTech Forum, 19 February, as part of the SEMI Technology Unites Global Summit, 15-19 February 2021, online event. Join us to meet experts from imec and other key industry influencers. Registration is open. SEMI: What is driving innovation in diagnostics and what is the role played by the semiconductor industry? Agell: There is a clear need for remote diagnostics triggered by the COVID-19 pandemic. Two examples are respiration monitoring and SARS-CoV2 testing technologies. The fact that some of the more obvious symptoms of COVID-19 are respiratory has revealed a big gap in medtech: the need for low-friction, ambulatory, continuous and pervasive respiratory monitoring solutions. At imec we have been working on bioimpedance-based technologies (from chipsets to smartphone-enabled sensing devices) that can provide feasible solutions in that space. Hence, novel sensing modalities from the semiconductor industry can make a difference when it comes to remote ambulatory respiratory monitoring. On the other hand, SARS-CoV2 diagnostic technologies have become paramount during the health crisis. In this space there is a clear need to simplify, speed up and lower the cost of testing. Additionally, from a practical perspective society needs to prevent virus spreading. imec is spearheading an innovative semiconductor-based solution aimed at simplifying SARS-CoV2 testing by collecting aerosols from subjects’ breath using a silicon-based solution for analysis using the polymerase chain reaction (PCR) method, the gold standard in COVID-19 testing. Determining viral load in exhaled breath is a clear indicator of infectiousness, and detecting subjects with a high viral load is key when developing these rapid tests to facilitate economic recovery. A cost-effective and speedy though reliable SARS-CoV2 testing solution opens up possibilities for its use as gating mechanism (such as testing to allow access to facilities and prior to boarding a plane) to help jump-start some of the hardest-hit sectors in the economy, such as travel and hospitality (hotels and restaurants) by enabling more in-person interactions. SEMI: Please share more about imec’s commitment to improving the healthcare sector. Agell: imec R D is active in the field of remote unobtrusive respiration solutions, which are vital in treating respiratory system conditions such as asthma, chronic obstructive pulmonary disease (COPD) and COVID-19. These solutions rely on a combination of silicon chipsets, sensor integration and algorithms to interpret sensor data. As part of our effort to understand biological fundamentals, imec’s multi-electrode array (MEA) platform for heart-on-chip applications offers unparalleled capabilities to acquire high-density information (4444 electrodes/mm2) to enable extra- and intracellular recordings, electrical stimulation and impedance gauging to study patient-derived cardiomyocytes, cells that make up the heart muscle. imec is developing a rapid, low-cost SARS-COV2 test based on breath analysis (aerosol capture) aimed at a 5-minute analysis. Such tool is a key to economic recovery, and imec is planning large-scale testing of the prototype device at Brussels Airport later in 2021. imec has recently supported spinoffs and external companies that develop social distancing tools for usage during the pandemic. Healthcare is a key strategic area at imec, with multiple departments working on complementary topics, ranging from cell-sorting technologies and multi-electrode arrays, through sensors and systems for non-invasive cardiorespiratory and neurological monitoring, all the way to advanced processing of medical data and tooling for trials. SEMI: How is the pandemic impacting remote diagnostics? What’s new in that field? Agell: The pandemic has accelerated advances in remote diagnostics for healthcare – for example making remote doctor visits possible and launching telehealth into a successful sector. But in my opinion, this is just the starting point. Telehealth doctors will soon need to collect health data points such as body temperature, weight, or blood pressure remotely, the same information they collect during an office visit. Soon thereafter though, doctor’s will need more and more data, sparking the next stage of advances in remote diagnostics as algorithms are developed to analyze sizeable amounts of data. All in all, it will result in a big move from doctor-centric paradigms to more patient-centric solutions. Hopefully that jump will also drive a more proactive approach to health, enabling prevention and keeping people healthy, and leaving behind the era of curing the sick. imec research tools for respiratory monitoring will come in the form of a health patch. SEMI: Besides infectious disease diagnostics, what solutions will enable a paradigm shift? Can you name two global market trends related to the rising need for remote diagnostics? Agell: The paradigm shift in healthcare will be largely fueled by the hyperconnectivity trend. Communications are fast and far-reaching. The pandemic has proven that healthcare, similar to retail, banking, trading and business in general, can also be done partly remotely through a communications line. The need for proof of performance in the case of diagnostics has been proven challenging, due to the highly regulated medical field and the general conservativeness of this market. There is a clear trend underway in which algorithms and automated diagnostics are slowly gaining the trust of the medical community. Trials and regulatory submissions will help here, but the clear proof will be the general trust of the medical community (and general population) in solutions that have been on the market for a while. Similar to what happened with GPS navigation technologies back in the day, it would require a critical mass to reach general acceptance. As far as the healthcare market is concerned, there is a forecast bounce back from telehealth into hybrid models (a mix between in-office visits and telehealth) as a first post-pandemic scenario. Although this is perceived as the best of both worlds, its effectiveness and survival within the market is still to be proven. A clear market trend accelerated by the pandemic is the commoditization of health and wellness features in consumer electronics. A glimpse into consumer electronics venues reveals that watches, smartphones, weight scales and even your office chair or mattress will soon be collecting healthcare information. imec MultiElectrode Array (MEA) chipset SEMI: What is imec’s role in addressing the challenges and trends in healthcare? Agell: As an R D organization, imec offers expertise in the semiconductor, integration, data interpretation, data management and health-specific application domains. Thanks to our experience in horizontal technology and multiple application domain verticals (including healthcare), imec provides solutions to partners that push the boundaries of performance in health-tangential fields such as communications, consumer electronics, automotive and energy. imec is part of big European initiatives aiming to tackle the challenges of the pandemic. For example, we recently started working on the Digipredict project, which aims at early intervention in infectious diseases. We’re working with key players in the research domain within the EU such as École Polytechnique Fédérale de Lausanne, University of Twente and Eidgenössische Technische Hochschule Zürich. Additionally, imec has worked for market leaders in the healthcare sector such as Philips and Biotelemetry (recently integrated in Philips) and can help partners make the next health solution a reality. SEMI: How can technology unite us? What do you expect from your participation at SEMI Technology Unites Global Summit? Agell: I am a big optimistic on this pandemic. I believe technology has played a key role in putting boundaries around damage caused by the global health crisis. Technology does not only unite us, but it arguably saves lives! My personal expectation for the SEMI Technology Unites Global Summit is for us to get a better understanding about how the semiconductor industry reacts to a pandemic and upcoming post-pandemic scenario. I am curious to see if health-related trends emerge, and whether this is a transitory effect. During the last global pandemic, the semiconductor industry was not even existing, so there is no clear precedent for the current situation. Carlos Agell, program manager and principal member of Technical Staff at imec, where he oversees the development of projects and sets strategy directions for research topics. He has a background in wearable device development, having taken leadership roles in development of two FDA-approved medical devices in the field of wearable cardiology. He is member of the Dutch chapter of the standardization committee, which develops next-generation international standards for active medical devices. Carlos Agell holds two MSc degrees in Electronics Engineering and EECS from the Polytechnical University of Catalonia (Spain) and the University of California in Irvine (Irvine, CA, USA). Serena Brischetto is senior manager of Marketing and Communications at SEMI Europe.

“A hundred years from now, someone’s going to look back and say, ‘Can you believe they waited until you got a disease, and then they did something?’” This observation from Dr. William Hait, the leader of Johnson Johnson’s External Innovation program, crisply sums up the SEMI Smart MedTech Summit, a two-day program at SEMICON Europa 2019, sponsored by GE Research and imecBenjamin Wiegand, PhD of Johnson Johnson, cited the quote in his opening presentation and added another pertinent question: “What if we could predict who was going to get a disease and then preempt it from happening?” Weigand’s conclusion is the first of six key takeaways from the summit.1. Accomplishing this vision could lead to a world without disease. Developing a disease-free world by exploring how the integration of advanced electronics and medical technology (MedTech) can enable new healthcare solutions is the very mission of the SEMI Smart MedTech Initiative. Various experts speaking at the MedTech Summit delved into a range of topics, from pan-European medical initiatives and artificial organs to new sensors and systems and start-ups’ need for funding and partners.2. All of us will have a digital twin (avatar), bringing together all relevant data that can impact our health and well-being.Several speakers illustrated the advantages of a digital human avatar that would start with an individual’s unique physical data and then be continuously updated with new data tracked by body-worn devices and from ongoing research findings. This would enable healthcare providers to extract insights and predict future physical performance or health issues.While, technologically, the avatar can already be constructed, the ability to make real changes to future human behavior is a significant outstanding question. Multiple speakers highlighted the various benefits of digital avatars at the MedTech Summit. 3. The MedTech sector’s need for cybersecurity looms large, as it does in every other digitally-driven, IOT-based framework.Further exploring the human-to-digital interface, Anthony Mathur of Bart’s Heart Center in the UK pointed to the importance of strict laws for safeguarding patient privacy, a cornerstone of healthcare digital policies, and the critical need for cybersecurity. He warned against an all-digital action network, citing the virus attack that shut down the UK’s National Health Service, rendering all patient records inaccessible for more than two weeks.4. MedTech devices, systems and other tools will radically change healthcare in the not-too-distant future.Almost every speaker touched on this point, including Franz Laermer of Bosch in his presentation The Future of Personalized Treatment. Laermer explored devices that will drive more patient-centric healthcare in areas including asthma therapy and molecular diagnostic testing and highlighted innovations in monitoring oncology therapies more effectively, less invasively and more accurately. Other presenters showcased their work in areas including silicon-based microfluidics, next-generation DNA sequencing and synthesis, lab-on-chip and cell arrays. 5. Startups and well-established companies will help advance digital tools and data to keep us healthier, happier and safer. Among the MedTech Summit highlights, several start-ups presented their business, financial and go-to-market plans. Notably, continuous glucose monitoring (CGM) is an especially active area of investment and innovation, as diabetes is among the world’s most widespread chronic diseases. The industry’s goal is to develop a non-invasive platform as a replacement for today’s prick-and-test approach to measuring blood sugar levels.6. Pan-European organizations are working to coordinate efforts and investments in digital healthcare. The European healthcare sector is large and diverse, as shown in the following slide provided by the organization MedTech Europe. Every country has its own legal framework, infrastructure, and health service structure medical technology companies must navigate. More than 27,000 medtech companies are located in Europe – 95% of them small to medium size businesses. Michael Stubin and Patrick Boisseau from MedTech Europe said concerted efforts to coordinate research and structural changes across the EU are underway to help spur medtech innovation and, with healthcare accounting for 10% of Europe's GDP, drive more market opportunity. This table shared by MedTech Europe points to the wide range of medical systems by country across the continent. Next StepsIs your company applying microelectronics innovations to change the way we approach medical care? If so, you’re invited to share your mission, roadmap and collaboration needs at a future MedTech Initiative Forum. For regular updates, join the MedTech interest list. In addition to the SEMI MedTech Initiative, our Nano-Bio Materials Consortium (NBMC) brings together scientists, engineers and business development professionals from industry, government and universities to collaboratively initiate research and development of electronic technologies to improve human performance monitoring and performance augmentation. Find out more at www.semi.org/collaborate/communities/NBMC.Michael Ciesinski is the Vice President of Technology Communities at SEMI.

Healthcare has traditionally focused on one-size fits-all medication to treat populations instead of tailoring treatments to individual patients. Recent advances in stem cell technology allow researchers to create disease models for personalized medicine. SEMI spoke with Thomas Pauwelyn, Postdoctoral Researcher at imec, about trends in medical technology innovation such as organ-on-chip devices and their applications. Pauwelyn shared his views ahead of his presentation at the SEMI SMART MedTech Forum, 13-14 November, in Hall B2 (Inspiration Hub) at SEMICON Europa, 12-15 November, 2019, in Munich, Germany. Join us at the event to meet experts from imec.xpand and other key industry influencers. Registration is open. Participation is free of charge for SEMICON Europa visitors. SEMI: What triggered the healthcare move from a one-size fits-all medication to treat populations to tailored treatments? What advancements allowed researchers to create models for personalized medicine? Pauwelyn: One of the main triggers for this transition is the inefficiency of the current healthcare system. The top 10 highest grossing drugs in the U.S. are effective for only between 1 in 25 to 1 in 4 patients. Not only do most medicines only help a small share of the patients, but they are often developed in classical clinical trials with predominantly western or male participants.Recent advances in stem cell technology allow researchers to create disease models for individual patients. In other words, researchers can reprogram cells from a patient’s skin or blood sample to various cell types, including cardiac or neuronal cells, through stem cell techniques. These samples reflect the traits that make a patient unique.However, patient-in-a-dish models expose cells to very artificial environments. So these models look very different from their counterparts in the body. Organ-on-chip systems address these issues by exposing cells to physiologically relevant conditions and create more mature models. SEMI: What is exactly an organ-on-chip? Pauwelyn: Organ-on-chip devices are microfluidic cell culture chips that can revolutionize the development of drugs and personalized treatments. These devices model the pathophysiological behavior of organs and tissues. Inside these chips, cell cultures are grown and exposed to conditions that better resemble in vivo microenvironment. Different organ models can be created by exposing different cell types to an engineered microenvironment. Common examples are the heart-on-chip, lung-on-chip, gut-on-chip or brain-on-chip.SEMI: Medical technology has made astonishing advances over the years. As new medical devices emerge, what are the main challenges?Pauwelyn: Meeting stringent regulatory requirements is one of the main challenges for medical devices. Technologies related to personalized medicine do not neatly fit in existing health technology assessments and reimbursement processes.In the case of organ-on-chip devices, there are challenges related to production, qualification and adoption. Increased standardization will also help scientists compare and interpret their findings. Currently, various research groups obtain different results from own organ-on-chip systems. These systems may be fabricated from different or exotic materials, expose cells to different microenvironments or rely on other cell models. Often, only a few devices are available for testing due to limited fabrication scalability.SEMI: What did imec do to overcome those challenges?Pauwelyn: imec turned to its expertise in chip design and technology to develop a novel organ-on-chip platform in close collaboration with Micronit Microtechnologies in the InForMed project funded by the ECSEL Joint Undertaking (ECSEL2014-2-662155). The platform’s main requirements were that it could reduce handling variability by microfluidic automation, be fabricated with conventional materials compatible with production upscaling, and produce high-quality electrical recordings of cellular activity. Another essential requirement was the compatibility of the device to the standard workflow of pharmaceutical research. The user interface is based a conventional 96-well plate, and peristaltic pumps are integrated into the device.SEMI: How does the CMOS-based microelectrode array work and where do you see potential for applications in the field of personalized medicine?The imec-developed CMOS-based microelectrode array is the sensor in our organ-on-chip system that monitors the cell culture. The sensor consists of 16,384 electrodes distributed over 16 independent microfluidic wells. It detects cellular activity down to the single-cell level, including intracellular action potentials or extracellular signals from electrically active cells or impedance caused by cells growing directly over the electrode.We believe this technology has great potential for developing miniaturized patient models in the lab. By using patient cells reprogrammed to the desired cell types through stem cell technologies, we can develop patient-on-chip systems. These systems would be able to predict which treatment is best suited for a specific patient or how drugs affect certain subpopulations.SEMI: What are your expectations for the SMART MedTech Forum at SEMICON Europa 2019 in Munich? Pauwelyn: The SMART MedTech Forum brings together an interesting mixture of researchers, entrepreneurs and stakeholders in the future of healthcare. I look forward to hearing their perspectives and to discuss how personalized medicine and MedTech will help tackle current challenges.SEMI: Can you share one prediction for the future of MedTech? Pauwelyn: I believe that MedTech in the future will help us tailor treatments to each patient. Doctors will have a wide arsenal of tools available to predict which treatment will deliver both the highest chance of success and the lowest chance of adverse reactions. One of these tools could be a human-patient-on-chip system. It would consist of interlinked organ-on-chip modules with patient-derived cell models. In this way, the reaction of patients to specific treatments could be predicted without ever exposing them to potentially harmful compounds.Dr. Thomas Pauwelyn currently is a post-doctoral researcher with an Innovation Mandate grant from VLAIO, investigating strategies to valorize the results from his research. Pauwelyn’s research focuses on developing novel organ-on-chip systems for predictive toxicology and drug development. He also investigates how organ-on-chip devices may help stratify patients and help enable personalized medicine. Pauwelyn has studied at KU Leuven, Belgium, since 2008. He earned his BSc in Bioscience Engineering specializing in Catalytic Technologies in 2011 and a Master’s in Nanoscience and Nanotechnology with the Bioscience Engineering option in 2013. He completed an IWT fellowship for a PhD at KU Leuven and imec’s Life Science Technologies group in 2018.Serena Brischetto is senior manager, marketing and communications, at SEMI Europe.